Inactive Instrument

Lexicon Pharmaceuticals, Inc. Stock price Nasdaq

Equities

US5288721047

Biotechnology & Medical Research

Sales 2024 * 18.65M Sales 2025 * 77.52M Capitalization 539M
Net income 2024 * -186M Net income 2025 * -163M EV / Sales 2024 * 28.9 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 6.96 x
P/E ratio 2024 *
-3.08 x
P/E ratio 2025 *
-3.45 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.01%
More Fundamentals * Assessed data
Dynamic Chart
Lexicon Pharmaceuticals Files Prospectus for Secondary Offering MT
Lexicon Pharmaceuticals Shares Decline After Analysis Finds Similar Effect of Sotagliflozin in Type 1 Diabatic Patients MT
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease CI
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup DJ
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Decline in Afternoon Trading MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Jump MT
Lexicon Pharmaceuticals Q4 Net Loss Widens, Revenue Rises; to Resubmit NDA for Sotagliflozin; Shares Gain Pre-Bell MT
Lexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for Sotagliflozin DJ
Earnings Flash (LXRX) LEXICON PHARMACEUTICALS Reports Q4 Revenue $702,000 MT
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Lexicon Pharmaceuticals, Inc Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA CI
Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding CI
Transcript : Lexicon Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM
More news
Managers TitleAgeSince
Chief Executive Officer 58 14-07-06
Director of Finance/CFO 59 98-12-31
Chief Tech/Sci/R&D Officer 60 21-08-01
Members of the board TitleAgeSince
Director/Board Member 79 01-01-31
Chairman 69 07-07-31
Director/Board Member 65 07-08-27
More insiders
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Related indices
More about the company
  1. Stock
  2. Equities
  3. Stock Lexicon Pharmaceuticals, Inc.
  4. Stock Lexicon Pharmaceuticals, Inc. - Nasdaq